Compare AAP & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | BLLN |
|---|---|---|
| Founded | 1929 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2002 | N/A |
| Metric | AAP | BLLN |
|---|---|---|
| Price | $51.43 | $67.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 7 |
| Target Price | $53.50 | ★ $129.57 |
| AVG Volume (30 Days) | ★ 1.8M | 315.4K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $8,601,000,000.00 | N/A |
| Revenue This Year | $0.55 | $35.42 |
| Revenue Next Year | $2.46 | $32.30 |
| P/E Ratio | $72.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.89 | $61.96 |
| 52 Week High | $70.00 | $138.70 |
| Indicator | AAP | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 38.30 |
| Support Level | $49.13 | $66.00 |
| Resistance Level | $53.13 | $100.28 |
| Average True Range (ATR) | 2.17 | 6.70 |
| MACD | -0.37 | -0.91 |
| Stochastic Oscillator | 36.46 | 22.87 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.